Xenetic Biosciences, Inc. XBIO
Set alert
2.05 USD -0.07 -3.30%
At close · Oct 30
2.07 +0.02 +0.98%
After hours · Oct 30, 4:00 PM ET
1.95 Day range 2.15
1.72 52-week range 4.67
- YTD
- -5.53%
- 1 year
- -37.69%
- Open
- 2.14
- Prev close
- 2.12
- Mkt cap
- 4.80M
- Vol
- 32.62K
- Avg vol
- 90.07K
- EPS
- -1.15
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.95
- High
- 2.15
- Forward P/E
- -6.20
- Beta
- 2.26
- Short ratio
- 0.77
- Inst. own
- 2.10%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.99
- 200-d avg
- 4.00
- 1y target
- 0.00
Financial health
Altman Z-Score
-36.93 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 4
Valuation
P/E -1.4×
FY 2016 5y median -1.4× FY 2025
P/S 1.2×
FY 2016 5y median 2.4× FY 2025
P/B 0.5×
FY 2016 5y median 0.5× FY 2025
P/FCF -1.6×
FY 2016 5y median -1.6× FY 2025
EV/EBITDA 1.6×
FY 2016 5y median 0.9× FY 2025
EV/Sales -1.4×
FY 2016 5y median -1.5× FY 2025
FCF Yield -61.9%
FY 2016 5y median -61.9% FY 2025
Profitability
Gross Margin 100.0%
FY 2016 5y median 100.0% FY 2025
Operating Margin -95.2%
FY 2016 5y median -177.8% FY 2025
Net Margin -90.1%
FY 2016 5y median -162.8% FY 2025
ROE -36.2%
FY 2016 5y median -42.2% FY 2025
ROIC -38.3%
FY 2016 5y median -46.1% FY 2025
ROA -32.1%
FY 2016 5y median -39.0% FY 2025
Growth (YoY)
Revenue 19.0%
FY 2016 FY 2025
Operating Income 32.6%
FY 2016 FY 2025
EPS (diluted) 38.5%
FY 2016 FY 2025
Free Cash Flow 18.8%
FY 2016 FY 2025
Financial Health
Current Ratio 8.3×
FY 2016 5y median 11.8× FY 2025
Quick Ratio 8.3×
FY 2016 5y median 11.8× FY 2025
Debt / Equity 0.0×
FY 2016 5y median 0.0× FY 2025
Net Debt / EBITDA 2.9×
FY 2016 5y median 2.2× FY 2025
Interest Coverage 0.0×
FY 2016 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31